Effect of L. (Okra) on Dyslipidemia: Systematic Review and Meta-Analysis of Clinical Studies.

The global prevalence of cardiovascular diseases (CVDs), including dyslipidemia and atherosclerosis, is rising. While pharmacological treatments for dyslipidemia and associated CVDs exist, not all individuals can afford them, and those who do often experience adverse side effects. Preclinical studies have indicated the potential benefits of and its active phytochemicals in addressing dyslipidemia in rodent models of diabetes. However, there is limited clinical evidence on lipid parameters. Thus, this study aimed to assess the potential impact of on dyslipidemia. A literature search was performed on PubMed, Scopus, and Cochrane Library for relevant trials published from inception until 11 August 2024. Data analysis was performed using Jamovi software version 2.4.8 and Review Manager (version 5.4), with effect estimates reported as standardized mean differences (SMDs) and 95% confidence intervals (CI). The evidence from eight studies with nine treatment arms showed that reduces total cholesterol (TC), SMD = -0.53 (95% CI: -1.00 to -0.07), = 0.025), compared to placebo. Additionally, triglyceride (TG) was reduced in compared to placebo, SMD = -0.24 (95% CI: -0.46 to -0.02), = 0.035. Furthermore, low-density lipoprotein (LDL) was also reduced, SMD = -0.35 (95% CI: -0.59 to -0.11), = 0.004 in versus placebo. This remedy substantially increased high-density lipoprotein (HDL), SMD = 0.34 (95% CI: 0.07 to 0.61), = 0.014). substantially improved lipid profile in prediabetes, T2D, obesity, and diabetic nephropathy. While the evidence confirms the potential benefits of in reducing dyslipidemia, it is important for future clinical studies to standardize the effective dosage for more reliable results. Therefore, future trials should focus on these markers in well-designed trials with sufficient sample sizes. Furthermore, can be supplemented to the diet of the relevant populations to alleviate dyslipidemia.